Immunology and Biotherapies

SummaryBackground

One-third of patients with Crohn's disease (CD) or ulcerative colitis (UC) receiving anti-TNFs do not respond to treatment, and a relevant proportion experience loss of response or intolerance.

Aim

To investigate the efficacy and safety of a second anti-TNF agent after primary/secondary failure or intolerance to a first drug.

Methods

Inclusion criteria: studies evaluating the efficacy of infliximab (IFX), adalimumab (ADA) and certolizumab-pegol (CZP) as the second anti-TNF in CD or UC. Search strategy: Bibliographical searches (PubMed/Embase). Data synthesis: percentage of response/remission; the meta-analysis was performed using the inverse variance method.

Results

We included 46 studies (37 CD, 8 UC, 1 pouchitis). The CD studies comprised 32 switching IFXADA, 4 IFXCZP and 1 ADAIFX. Overall, the second anti-TNF after the failure of IFX in CD induced remission in 43% and response in 63% of patients. The remission rate was higher when the reason to withdraw the first anti-TNF was intolerance (61%) than after secondary (45%) or primary failure (30%); response rates were, respectively, 72%, 62% and 53%. All UC studies switched IFXADA, six of them reporting remission rates ranging from 0% to 50%. Adverse events rate ranged from 0% to 81% in CD, most of them mild (serious adverse event 0–21%, discontinuation rate <20%).

Conclusions

The efficacy of a second anti-TNF in CD patients largely depends on the cause for switching. The remission rate is higher when the reason to withdraw the first anti-TNF is intolerance (61%), compared with secondary (45%) or primary failure (30%). Further studies of switch ADAIFX are needed to evaluate this strategy. PROSPERO-registry-number: CRD42014012943.

Via Krishan Maggon

Targeting pro-inflammatory cytokines such as tumour necrosis factor-α (TNF-α) has been an effective therapeutic approach in patients with a variety of autoimmune diseases, including psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, and ankylosing spondylitis. New targets along the interleukin-17 (IL-17)–TH17 (T helper cell 17) pathway, 

Via Krishan Maggon